Tag: M.W:100-200

Chemical Research Letters, May 2021. In heterogeneous catalysis, catalysts provide a surface to which reactants bind in a process of adsorption. 83249-10-9, Name is 3-(Methoxycarbonyl)bicyclo[1.1.1]pentane-1-carboxylic acid, molecular formula is C8H10O4, Product Details of 83249-10-9, belongs to benzisoxazole compound, is a common compound. In a patnet, author is Brodie, M. J., once mentioned the new application about 83249-10-9.

Zonisamide is a benzisoxazole derivative, chemically unrelated to other antiepileptic drugs, that appears to have multiple mechanisms of action, including inhibition of Na+ channels and reduction of T-type Ca2+ currents. It is currently licensed in Europe and the USA for adjunctive treatment of partial seizures in adults, and in Europe as monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy. Zonisamide displays predictable, dose-dependent pharmacokinetics and has a half-life of similar to 60 h, allowing once- or twice-daily administration. It has a low potential for interactions with other medications, including oral contraceptives. The clinical efficacy of adjunctive zonisamide therapy has been established in four pivotal, phase III, randomized, double-blind, placebo-controlled trials, which together included approximately 850 patients, aged 12-77 years, with refractory partial epilepsy. In all four trials, zonisamide 300-600 mg/day resulted in significant reductions in median total seizure rates vs placebo, and zonisamide was generally well tolerated; the most frequently reported adverse events being somnolence, dizziness and anorexia/weight loss. Subanalysis of the primary European trial indicated that zonisamide was effective when administered as first-line adjunctive treatment, and a long-term extension to the same trial demonstrated that the efficacy and safety/tolerability of adjunctive zonisamide was sustained for up to 36 months. Once-daily monotherapy with zonisamide (200-500 mg/day) has been shown to be non-inferior to, and as well tolerated as, twice-daily monotherapy with controlled-release carbamazepine (400-1200 mg/day) in adults with newly diagnosed partial epilepsy. Zonisamide has also been shown to have favourable long-term retention rates, an important indication of its overall effectiveness.

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 83249-10-9 help many people in the next few years. Product Details of 83249-10-9.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics

Research speed reading in 2021. Chemistry, like all the natural sciences, begins with the direct observation of nature— in this case, of matter. Category: Benzisoxazole, The reactant in an enzyme-catalyzed reaction is called a substrate. Enzyme inhibitors cause a decrease in the reaction rate of an enzyme-catalyzed reaction. 123-99-9, Name is Water-soluble azelaic acid, molecular formula is C9H16O4. In an article, author is Forconi, Marcello,once mentioned of 123-99-9.

Enzymes catalyze chemical reaction in aqueous media, but their active sites significantly differ in properties from water. In this chapter, the work on selected chemical reactions with important biological roles is reviewed to assess our current understanding of the effect of the environment that surrounds the reactive species. In particular, simple medium effects such as the ones provided by organic solvents, ionic liquids, and simple micelles are focused on. The findings that led to the computational design of enzymes that catalyze the Kemp elimination, a prototypical proton transfer reaction that has fascinated researchers for more than a century, are discussed.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions. you can also check out more blogs about 123-99-9. Category: Benzisoxazole.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics

New discoveries in chemical research and development in 2021.Name: 2,3-Dihydroxysuccinic acid, The reactant in an enzyme-catalyzed reaction is called a substrate. Enzyme inhibitors cause a decrease in the reaction rate of an enzyme-catalyzed reaction. 526-83-0, Name is 2,3-Dihydroxysuccinic acid, molecular formula is C4H6O6. In an article, author is Smith, Jessica A.,once mentioned of 526-83-0.

Background: 1,2-benzisoxazole derivatives have been the focus of numerous studies, due to their biological and chemical interest. Results: We demonstrate an efficient synthesis of a series of 3-amino-substituted 1,2-benzisoxazoles from a 3-chloro-1,2-benzisoxazole by microwave-promoted nucleophilic aromatic substitution. The 3-amino-1,2-benzisoxazoles prepared were obtained in 1-6 h in good-to-high yields of 54-90%. The 3-chloro-1,2-benzisoxazoles were also prepared by heating with microwave irradiation in quantitative yields in 2 h, from the corresponding 3-hydroxy-1,2-benzisoxazoles. Conclusion: This efficient microwave-assisted pathway could be applied to a variety of substrates in the further development of substituted 1,2-benzisoxazoles.

The proportionality constant is the rate constant for the particular unimolecular reaction. the reaction rate is directly proportional to the concentration of the reactant. I hope my blog about 526-83-0 is helpful to your research. Name: 2,3-Dihydroxysuccinic acid.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics

Research speed reading in 2021.The appropriate choice of redox mediator can avoid electrode passivation and overpotential, which strongly inhibit the efficient activation of substrates in electrolysis. , Computed Properties of https://www.ambeed.com/products/868-14-4.html, Introducing a new discovery about 868-14-4, Name is Potassium hydrogen tartrate, molecular formula is C4H5KO6, belongs to benzisoxazole compound. In a document, author is Sanai, T.

Neuroleptic malignant syndrome is a rare but potentially lethal, rare reaction to neuroleptics which is characterized by altered levels of consciousness, extrapyramidal effects, autonomic instability, hyperthermia, and elevated serum creatine phosphokinase levels. The most serious complication of neuroleptic malignant syndrome is acute renal failure. We investigated six cases of neuroleptic malignant syndrome associated with myoglobulinemic acute renal failure due to rhabdomyolysis and effect of hemodialysis or hemodiafiltration. The patients were five males and one female with a mean age of 43.5 yr. All of the patients, who developed acute renal failure induced from rhabdomyolysis, had previously received butyrophenone (haloperidol), phenothiazine, benzamide, iminomide, benzisoxazole, antidepressants, and hypnotics (benzodiazepine and barbiturate) for the treatment of schizophrenia. The clinical manifestations of neuroleptic malignant syndrome were characterized by altered consciousness, muscle rigidity and weakness, fever, and excessive perspiration. The peak laboratory data were blood urea nitrogen 102 26 (mean SD) mg/dL, serum creatinine 9.1 2.1 mg/dL, serum creatine phosphokinase 229,720 289,940 IU/L, and all of them developed oliguric acute renal failure. Dantrolene sodium administration was given to five cases and hemodialysis or hemodiafiltration was performed in all of them. The serum creatinine level after hemodialysis or hemodiafiltration was 1.4 1.0 mg/dL. All patients were successfully cured of acute renal failure by hemodialysis or hemodiafiltration. As a result, myoglobulinemic acute renal failure associated with neuroleptic malignant syndrome was successfully treated by hemodialysis or hemodiafiltration.

If you are interested in 868-14-4, you can contact me at any time and look forward to more communication. Computed Properties of https://www.ambeed.com/products/868-14-4.html.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics

Reference of 83249-10-9, New Advances in Chemical Research, May 2021.Reactions catalyzed within inorganic and organic materials and at electrochemical interfaces commonly occur, causing turnover rates to depend strongly on interfacial structure and composition. 83249-10-9, Name is 3-(Methoxycarbonyl)bicyclo[1.1.1]pentane-1-carboxylic acid, SMILES is O=C(C1(C2)CC2(C(OC)=O)C1)O, belongs to benzisoxazole compound. In a article, author is Hasegawa, H, introduce new discover of the category.

Objectives: Zonisamide (1,2-benzisoxazole-3-methanesulfonamide) is a novel antiseizure medication approved for use in the United States as adjunct therapy in the treatment of partial seizures in adults with epilepsy. It has also been used to treat other conditions including intractable pain. The aim of this study was to determine the usefulness of zonisamide in patients whose seizures were not controlled after having been treated with at least three other currently available anticonvulsant medications or in patients whose pain control was suboptimal despite the use of commonly used drug regimens. Methods: This was a retrospective study documenting the efficacy of zonisamide in 48 consecutive patients who presented at an outpatient neurology clinic at a Veterans Administration hospital. The patients were diagnosed with refractory partial seizures (n = 21) or a variety of intractable neuropathic pain syndromes (n = 27). Results: Sixteen out of 21 seizure patients (76%) experienced a 50% or greater reduction in seizure frequency when zonisamide (1100-200 mg daily) was added to their existing anticonvulsant medication regimen. Of 27 patients with neuropathic pain, 17 (59%) responded to zonisamide, reporting subjective reduction in pain by at least 50%. The most common adverse events were gastrointestinal upset, somnolence, and one case of skin rash. Conclusions: In this study, zonisamide appeared to be an effective adjunct therapy in the treatment of partial seizures in adults who continued to experience frequent episodes while taking other anticonvulsant medications, and in adults whose neuropathic pain was not well controlled with analgesics. These promising results must be tempered by the fact that this investigation included a small patient population in an uncontrolled study design. Further research into the efficacy and tolerability of zonisamide in these areas is warranted.

Reference of 83249-10-9, Enzymes are biological catalysts that produce large increases in reaction rates and tend to be specific for certain reactants and products. I hope my blog about 83249-10-9 is helpful to your research.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics

New Advances in Chemical Research in 2021. Irreversible inhibitors are therefore the equivalent of poisons in heterogeneous catalysis. 52356-01-1, Name is 2-Hydrazinobenzoic acid hydrochloride, molecular formula is C7H9ClN2O2, SDS of cas: 52356-01-1, belongs to benzisoxazole compound, is a common compound. In a patnet, author is Sano, Hiromi, once mentioned the new application about 52356-01-1.

Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by the loss of nigrostriatal dopaminergic neurons and consequent motor dysfunction. Zonisamide (1,2-benzisoxazole-3-methanesulfonamide), which was originally developed as an antiepileptic drug, has been found to have therapeutic benefits for PD. However, the pharmacological mechanisms behind the beneficial actions of zonisamide in PD are not fully understood. Here, we investigated the neuroprotective effects of zonisamide on nigrostriatal dopaminergic neurons of the Engrailed mutant mouse, a genetic model of PD. Chronic administration of zonisamide in Engrailed mutant mice was shown to improve the survival of nigrostriatal dopaminergic neurons compared with that under saline treatment. In addition, dopaminergic terminals in the striatum and the motor function were improved in zonisamide-treated Engrailed mutant mice to the levels of those in control mice. To clarify the mechanism behind the neuroprotective effects of zonisamide, the contents of neurotrophic factors were determined after chronic administration of zonisamide. Brain-derived neurotrophic factor content was increased in the striatum and ventral midbrain of the zonisamide-treated mice compared to saline-treated mice. These findings imply that zonisamide reduces nigrostriatal dopaminergic cell death through brain-derived neurotrophic factor signaling and may have similar beneficial effects in human parkinsonian patients as well.

Interested yet? Keep reading other articles of 52356-01-1, you can contact me at any time and look forward to more communication. SDS of cas: 52356-01-1.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics

New discoveries in chemical research and development in 2021.SDS of cas: 99189-60-3, The reactant in an enzyme-catalyzed reaction is called a substrate. Enzyme inhibitors cause a decrease in the reaction rate of an enzyme-catalyzed reaction. 99189-60-3, Name is 2-[1-(2-Amino-2-oxoethyl)cyclohexyl]acetic Acid, molecular formula is C10H17NO3. In an article, author is Katritzky, AR,once mentioned of 99189-60-3.

A series of 5-substituted-2,1-benzisoxazoles has been prepared by the reduction and subsequent cyclization of 5-substituted-2-nitrobenzaldehydes. Reactions of 5-piperidino-2,1-benzisoxazole with nitrous acid and of 5-hydroxy-, 5-N, N-dimethylamino- or 5-pyrrolidino-2,1-benzisoxazole with phenyldiazonium ion led to four 4,5-disubstituted-2,1-benzisoxazoles.

Interested yet? Read on for other articles about 99189-60-3, you can contact me at any time and look forward to more communication. SDS of cas: 99189-60-3.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics

New discoveries in chemical research and development in 2021.Recommanded Product: 2-Ethoxyacetic acid, The reactant in an enzyme-catalyzed reaction is called a substrate. Enzyme inhibitors cause a decrease in the reaction rate of an enzyme-catalyzed reaction. 627-03-2, Name is 2-Ethoxyacetic acid, molecular formula is C4H8O3. In an article, author is Hoy, Sheridan M.,once mentioned of 627-03-2.

Oral zonisamide (Zonegran (R)) is a benzisoxazole derivative chemically unrelated to other antiepileptic agents. It is indicated in the EU as monotherapy in the treatment of partial seizures, with or without secondary generalization, in adults with newly diagnosed epilepsy and as adjunctive therapy to other antiepileptic drugs (AEDs) in the treatment of adults with partial seizures, with or without secondary generalization. In a double-blind, multinational study in adults newly diagnosed with partial seizures, shorter-term monotherapy with once-daily zonisamide was noninferior to that with twice-daily carbamazepine controlled release in terms of seizure freedom according to the International League Against Epilepsy guidelines, with seizure freedom benefits maintained during longer-term therapy. In four randomized, double-blind, placebo-controlled studies in adults with refractory partial seizures, shorter-term adjunctive therapy with once-or twice-daily zonisamide reduced the frequency of seizures to a significantly greater extent than placebo, with antiepileptic efficacy sustained following longer-term treatment in this patient population. Zonisamide was generally well tolerated in adults with partial seizures participating in these studies, with the majority of adverse events being mild or moderate in severity. Thus, oral zonisamide as monotherapy or adjunctive therapy to other AEDs provides a useful option in the treatment of patients with partial seizures.

Interested yet? Read on for other articles about 627-03-2, you can contact me at any time and look forward to more communication. Recommanded Product: 2-Ethoxyacetic acid.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics

Reference of 3878-55-5, New Advances in Chemical Research, May 2021. Redox catalysis has been broadly utilized in electrochemical synthesis due to its kinetic advantages over direct electrolysis. 3878-55-5, Name is 4-Methoxy-4-oxobutanoic acid, SMILES is C(C(OC)=O)CC(O)=O, belongs to benzisoxazole compound. In a article, author is Clausen, RP, introduce new discover of the category.

The system of GABA transporters in neural cells constitutes an efficient mechanism for terminating inhibitory GABAergic neurotransmission. This transport system is an important therapeutical target in epileptic disorders, but potentially also in other neurological disorders. Thus, selective intervention in GABA uptake has been the subject of extensive research for several decades. In a series of lipophilic diaromatic derivatives of (RS)3-hydroxy-4-amino-4,5,6,7-tetrahydro-1,2-benzisoxazole (exo-THPO), N-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-hydroxy-4-(methylamino)4,5,6,7-tetrahydrobenzo[d]isoxazol-3-ol (EF1502) turned out to be an equipotent inhibitor at the mouse transporters GAT1 and GAT2 (BGT-1) but inactive at GAT3 and GAT4. This novel pharmacological profile among GABA uptake inhibitors prompted a thorough investigation of the in vivo properties of this compound. These investigations have for the first time demonstrated a functional role for GABA transporter subtype GAT2/ BGT-1, which points to the therapeutic relevance of inhibiting this transporter subtype. An overview of the development and characterisation of EF1502 is presented here. (C) 2006 Elsevier Ltd. All rights reserved.

Reference of 3878-55-5, Because enzymes can increase reaction rates by enormous factors and tend to be very specific, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 3878-55-5.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics

Related Products of 40052-13-9, New discoveries in chemical research and development in 2021. Chemo-enzymatic cascade processes are invaluable due to their ability to rapidly construct high-value products from available feedstock chemicals in a one-pot relay manner. 40052-13-9, Name is 3-Tert-butoxy-3-oxopropanoic acid, SMILES is CC(C)(C)OC(=O)CC(O)=O, belongs to benzisoxazole compound. In a article, author is Jain, M, introduce new discover of the category.

Several 1,2-benzisoxazole phosphorodiamidates have been designed as prodrugs of phosphoramide mustard requiring bioreductive activation. Enzymatic reduction of 1,2-benziosoxazole moiety is expected to result in the formation of imine intermediate due to the cleavage of the N-O bond. The imine should then be spontaneously hydrolyzed to a ketone metabolite, thereby facilitating base-catalyzed beta-elimination of cytotoxic phosphoramide mustard. As expected, the proposed prodrugs 4, 9, and 12 were at least 3-5-fold more potent cytotoxins than control compounds 5 and 15, which lack in the phosphoramide mustard group. Upon incubation with phenobarb-induced rat liver S-9 fraction, compounds 4, 9, and 12 underwent extensive NADPH-dependent metabolism with concomitant generation of alkylating activity under both hypoxic and oxic conditions. Corresponding ketone metabolites were detected for 9 and 15. NADPH-dependent bioreduction of 15 to its ketone metabolite 16 was located in the microsomal fraction and inhibited by SKF-525A and pCMBA. Compared with phenobarb-induced rat liver microsomal fraction, incubation of 15 with rat or human P450 reductase microsomes showed moderate generation of 16. Microsomal cytochrome P450 and/or P450 reductase appear to be involved in the reductive metabolism of 1,2-benzisoxazole moiety under hypoxic as well as oxic conditions.

Related Products of 40052-13-9, Consequently, the presence of a catalyst will permit a system to reach equilibrium more quickly, but it has no effect on the position of the equilibrium as reflected in the value of its equilibrium constant.I hope my blog about 40052-13-9 is helpful to your research.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics